Hyaluronidase (ovine)
- Generic Name
- Hyaluronidase (ovine)
- Brand Names
- Vitrase
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 488712-31-8
- Unique Ingredient Identifier
- 64R4OHP8T0
- Background
Highly purified sheep hyaluronidase for administration by injection into the vitreous of the eye.
- Indication
For increase of absorption and distribution of other injected drugs and for rehydration.
- Associated Conditions
- Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma ( FL), Refractory Follicular Lymphoma, Relapsed Follicular Lymphoma, Non-progressive Follicular Lymphoma, Stable Follicular Lymphoma
- Associated Therapies
- Parenteral rehydration therapy, Improving resorption of radiopaque agents, To increase percutaneous drug absorption therapy
Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase)
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2013-03-18
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 65
- Registration Number
- NCT00198458
- Locations
- ๐บ๐ธ
Solano Clinical Research (A Division of Dow Pharmaceutical Sciences), Davis, California, United States
Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2013-03-15
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 750
- Registration Number
- NCT00198510
- Locations
- ๐บ๐ธ
Illinois Retina Associates SC, Chicago, Illinois, United States
๐บ๐ธRetina Center at Pali Momi, Aiea, Hawaii, United States
๐บ๐ธKing Y. Lee, MD, Shawnee Mission, Kansas, United States
Assessment of Intravitreous Injections of Vitrase for Inducing Posterior Vitreous Detachment
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2013-03-15
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 10
- Registration Number
- NCT00198471
- Locations
- ๐บ๐ธ
Edgar L. Thomas, MD, Beverly Hills, California, United States
๐บ๐ธValley Retina Institute, PA, McAllen, Texas, United States
๐บ๐ธRonni Lieberman, MD, New York, New York, United States
Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage
- Conditions
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2013-03-15
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 510
- Registration Number
- NCT00198497
- Locations
- ๐ฟ๐ฆ
Nasionale Hospital, Bloemfontein, South Africa
๐ต๐ฑKlinika Chorob Oczu, Bydgoszcz, Poland
๐ต๐ฑOphtalmology Clinic, Gdansk, Poland
Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase)
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2013-03-14
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 65
- Registration Number
- NCT00198419
- Locations
- ๐บ๐ธ
Solano Clinical Research (A Division of Dow Pharmaceutical Sciences), Davis, California, United States
Evaluation of Vitrase as a Spreading Agent
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2013-03-14
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 108
- Registration Number
- NCT00198484
- Locations
- ๐บ๐ธ
Donald E Beahm, MD, Great Bend, Kansas, United States
๐บ๐ธOphthalmic Consultants of Long Island, Rockville Centre, New York, United States
๐บ๐ธCornea Consultants, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.